2015 Patient Seminar (Chicago, IL)
Update on Latest Treatment Options
Cladribine and Rituximab in HCL
Presenter:
Dr. Farhad Ravandi, MD Anderson Cancer Center, USA (Presentation Slides and Audio)
BRAF Inhibitors in HCL
Presenter:
Dr. Thorsten Zenz, University of Heidelberg, Germany (Presentation Slides and Audio)
Ibrutinib for HCL
Presenter:
Dr. Jeff Jones, The Ohio State University Wexner Medical Center, USA (Presentation Slides and Audio)
Clinical Trials at the NIH
Presenter:
Dr. Robert Kreitman, National Institutes of Health/National Cancer Institute, USA (Presentation Slides and Audio)
Question & Answer Session
How long does it take for symptoms to appear? (Audio)
Presenters:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Dr. Francesco Forconi, Southampton University Hospital, United Kingdom
When should you start treatment? (Audio)
Presenters:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Dr. James Johnston, Manitoba Institute of Cell Biology, Canada
Is there a difference in outcome from treatment with Cladribine versus Pentostatin? (Audio)
Presenter:
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Are there any unique characteristics of patients who do not need treatment right away? (Audio)
Presenters:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Dr. James Johnston, Manitoba Institute of Cell Biology, Canada
Is fever a common reaction to treatment? Are reactions to treatment reduced the 2nd or 3rd time around? (Audio)
Presenters:
Dr. Con Tam, Peter MacCallum Cancer Centre, Australia
Dr. James Johnston, Manitoba Institute of Cell Biology, Canada
Are there practical ways to help your immune system recover from treatment? (Audio)
Presenters:
Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom
Dr. Con Tam, Peter MacCallum Cancer Centre, Australia
What is recommended for patients that relapse after shorter than expected remission intervals? (Audio)
Presenters:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Is a bone marrow biopsy recommended after initial treatment? If so, when? (Audio)
Presenters:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Dr. Claire Dearden, The Royal Marsden; Con Tam, M.D., Peter MacCallum Cancer Centre, Australia
Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom
Is the profile of patients with HCL changing? (Audio)
Presenter:
Dr. Graeme Quest, University of Toronto, Canada
Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Are there any risks associated with vaccinations? (Audio)
Presenter:
Dr. Claire Dearden, The Royal Marsden, United Kingdom
What is the relation between HCL and other skin cancers and autoimmune diseases? (Audio)
Presenters:
Dr. James Johnston, Manitoba Institute of Cell Biology, Canada
Dr. Con Tam, Peter MacCallum Cancer Centre, Australia
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA
Does anyone have experience with long-term management of Cryptococcal Meningitis in HCL patients? (Audio)
Presenter:
Dr. Michael Grever, The Ohio State University Wexner Medical Center, USA